Multiparametric radiobiological assays show that variation of X-ray energy strongly impacts relative biological effectiveness: comparison between 220 kV and 4 MV.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 10 2019
Historique:
received: 19 06 2019
accepted: 20 09 2019
entrez: 6 10 2019
pubmed: 6 10 2019
medline: 12 11 2020
Statut: epublish

Résumé

Based on classic clonogenic assay, it is accepted by the scientific community that, whatever the energy, the relative biological effectiveness of X-rays is equal to 1. However, although X-ray beams are widely used in diagnosis, interventional medicine and radiotherapy, comparisons of their energies are scarce. We therefore assessed in vitro the effects of low- and high-energy X-rays using Human umbilical vein endothelial cells (HUVECs) by performing clonogenic assay, measuring viability/mortality, counting γ-H2AX foci, studying cell proliferation and cellular senescence by flow cytometry and by performing gene analysis on custom arrays. Taken together, excepted for γ-H2AX foci counts, these experiments systematically show more adverse effects of high energy X-rays, while the relative biological effectiveness of photons is around 1, whatever the quality of the X-ray beam. These results strongly suggest that multiparametric analysis should be considered in support of clonogenic assay.

Identifiants

pubmed: 31586152
doi: 10.1038/s41598-019-50908-4
pii: 10.1038/s41598-019-50908-4
pmc: PMC6778087
doi:

Substances chimiques

Genetic Markers 0
H2AX protein, human 0
Histones 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

14328

Références

Radiat Res. 2016 Mar;185(3):246-56
pubmed: 26930380
Br J Radiol. 2018 Sep;91(1089):20170762
pubmed: 29630386
Aging (Albany NY). 2011 Feb;3(2):168-74
pubmed: 21325706
IEEE Trans Pattern Anal Mach Intell. 1986 Jun;8(6):679-98
pubmed: 21869365
J Exp Med. 1956 May 1;103(5):653-66
pubmed: 13319584
Mutat Res. 2004 Nov 22;556(1-2):209-15
pubmed: 15491649
Radiat Res. 2015 Jan;183(1):82-93
pubmed: 25536232
Mol Cell. 2018 Aug 16;71(4):581-591.e5
pubmed: 30057196
Med Phys. 2009 Aug;36(8):3381-4
pubmed: 19746770
Radiat Oncol. 2014 Jan 14;9:26
pubmed: 24422711
Nat Protoc. 2009;4(12):1798-806
pubmed: 20010931
Radiat Res. 2005 May;163(5):510-9
pubmed: 15850412
PLoS One. 2012;7(4):e35740
pubmed: 22563394
Trends Cell Biol. 2018 Jun;28(6):436-453
pubmed: 29477613
Cell Cycle. 2010 Feb 15;9(4):662-9
pubmed: 20139725
Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40
pubmed: 17667954
Free Radic Biol Med. 2017 Jul;108:750-759
pubmed: 28431961
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Ann ICRP. 2003;33(4):1-117
pubmed: 14614921
Cytometry. 1994 Oct 1;17(2):185-9
pubmed: 7530620
Acta Oncol. 2017 Nov;56(11):1374-1378
pubmed: 28820311
Methods Mol Med. 2005;110:21-8
pubmed: 15901923
Cell Mol Life Sci. 2014 Nov;71(22):4373-86
pubmed: 25080110
Free Radic Res. 2010 Jun;44(6):587-604
pubmed: 20370560
Mutagenesis. 2012 Nov;27(6):645-52
pubmed: 22914676
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):191-203
pubmed: 9747838
Methods Mol Biol. 2007;371:21-31
pubmed: 17634571
Radiat Environ Biophys. 2003 Apr;42(1):55-61
pubmed: 12720002
J Radiat Res. 2018 May 1;59(3):253-260
pubmed: 29800455
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):353-361
pubmed: 28479002
Radiat Oncol. 2014 Dec 18;9:266
pubmed: 25518850
Mutat Res. 2017 Mar;797-799:15-25
pubmed: 28340407
Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):13-9
pubmed: 10656366
Radiat Prot Dosimetry. 2004;112(4):471-81
pubmed: 15623881
J Vis Exp. 2011 Mar 13;(49):
pubmed: 21445039
Strahlenther Onkol. 1999 Jun;175 Suppl 2:39-43
pubmed: 10394395
Int J Radiat Biol. 2018 Jun;94(6):597-606
pubmed: 29701998
PLoS One. 2016 Jan 04;11(1):e0145786
pubmed: 26727594

Auteurs

Vincent Paget (V)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France. vincent.paget@irsn.fr.

Mariam Ben Kacem (M)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Morgane Dos Santos (M)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of Radiobiology of Accidental exposures (LRAcc), Fontenay-aux-Roses, France.

Mohamed A Benadjaoud (MA)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Fontenay-aux-Roses, France.

Frédéric Soysouvanh (F)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Valérie Buard (V)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Tarlet Georges (T)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Aurélie Vaurijoux (A)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of Radiobiology of Accidental exposures (LRAcc), Fontenay-aux-Roses, France.

Gaëtan Gruel (G)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of Radiobiology of Accidental exposures (LRAcc), Fontenay-aux-Roses, France.

Agnès François (A)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Olivier Guipaud (O)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Fabien Milliat (F)

Institute for Radiological Protection and Nuclear Safety (IRSN), Department of RAdiobiology and regenerative MEDicine (SERAMED), Laboratory of MEDical Radiobiology (LRMed), Fontenay-aux-Roses, 92260, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH